EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease

Jaakko Rautakorpi, Sara Kolehmainen, Eliisa Löyttyniemi, Clas-Göran Af Björkesten, Perttu Arkkila, Taina Sipponen, Kimmo Salminen

Digestive Diseases and Sciences · 2025

DOI: 10.1007/s10620-025-08876-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Jaakko Rautakorpi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Abdominal Center - Department of Gastroenterology, University of Turku and Turku University Hospital, Turku, Finland. jaraut@utu.fi. Hauptthemen laut MEDLINE: Infliximab, Gastrointestinal Agents, Colitis, Ulcerative, Crohn Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Turku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recent studies suggest that subcutaneous infliximab is effective and safe for treating patients with inflammatory bowel disease. Real-world studies with larger cohorts are needed to confirm the efficacy of subcutaneous treatment. AIMS: The aim was to assess real-world treatment persistence, clinical outcomes, infliximab concentrations, and treatment safety after switching from intravenous to subcutaneous infliximab treatment with patients with inflammatory bowel disease. METHODS: This retrospective register-based study included patients with inflammatory bowel disease who were in clinical remission and switched from intravenous infliximab maintenance therapy to subcutaneous infliximab in two tertiary centers. RESULTS: A total of 274 patients (104 Crohn's disease and 170 ulcerative colitis) were included. After the switch, the treatment persistence at 12 months was 94.8% in patients with Crohn's disease and 88.8% in patients with ulcerative colitis. Only 11.3% (n = 31) of the patients discontinued the treatment during 79-week median follow-up. Compared to the baseline, no change occurred in clinical disease activity at the time points of 3, 6, and 12 months, based on the Harvey-Bradshaw Index or partial Mayo Score (p = 0.792 and p = 0.426, respectively). Infliximab median concentrations were higher (p < 0.0001) during subcutaneous treatment (16.75 µg/ml) compared to the intravenous treatment median trough levels before the switch (6.71 µg/ml). In total, 15.0% (n = 41) of the patients reported adverse events. CONCLUSION: Switching to subcutaneous infliximab maintenance therapy was associated with high treatment persistence, a stable disease course, increased infliximab concentrations, and an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabGastrointestinal AgentsColitis, UlcerativeCrohn DiseaseDrug SubstitutionHumansFemaleMaleRetrospective StudiesAdultInjections, SubcutaneousMiddle AgedTreatment OutcomeMaintenance ChemotherapyRegistriesYoung Adult

Stichwörter der Autor:innen

Biologic therapyCrohn’s diseaseIBDTumor necrosis factor inhibitorUlcerative colitis

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Abdominal Center - Department of Gastroenterology, University of Turku and Turku University Hospital, Turku, Finland. jaraut@utu.fi.
  • Faculty of Medicine, University of Turku, Kiinamyllynkatu 10, 20520, Turku, Finland. jaraut@utu.fi.
  • Abdominal Center - Department of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Department of Biostatistics, University of Turku and Turku University Hospital, Turku, Finland.
  • Abdominal Center - Department of Gastroenterology, University of Turku and Turku University Hospital, Turku, Finland.

Förderung

  • University of Turku

Zitieren

APA

Rautakorpi, J., Kolehmainen, S., Löyttyniemi, E., Björkesten, C. A., Arkkila, P., Sipponen, T., & Salminen, K. (2025). Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-025-08876-5

Vancouver

Rautakorpi J, Kolehmainen S, Löyttyniemi E, Björkesten CA, Arkkila P, Sipponen T, et al. Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-025-08876-5

BibTeX
@article{Rautakorpi2025,
  author = {Rautakorpi, Jaakko and Kolehmainen, Sara and Löyttyniemi, Eliisa and Björkesten, Clas-Göran Af and Arkkila, Perttu and Sipponen, Taina and Salminen, Kimmo},
  title = {Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease},
  journal = {Digestive Diseases and Sciences},
  year = {2025},
  doi = {10.1007/s10620-025-08876-5}
}
Kostenlos starten →